High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma

Jeffrey S. Abrams, Anthony A. Rayner, Peter H. Wiernik, David R. Parkinson, Mario Eisenberger, Frederick R. Aronson, Rasim A. Gucalp, Michael B. Atkins, Michael J. Hawkins

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

Sixteen patients with metastatic renal cell carcinoma were treated with high-dose bolus recombinant interleukin-2 (rIL-2) alone at a dose and schedule identical to those that produced a 35% response rate among 72 patients in a trial reported by the Surgery Branch, National Cancer Institute (NCI), Bethesda, Md, in which rIL-2 plus lymphokine-activated killer (LAK) cells was used for the treatment of renal cell carcinoma. Patients received two 5-day cycles of 100,000 Cetus U/kg (600,000 IU/kg) of rIL-2 infused intravenously over 15 minutes every 8 hours; each treatment cycle was separated by 1 week. No objective responses were seen. The toxicity of rIL-2 given alone at these high doses was similar to that noted with high-dose rIL-2-LAK cell therapy. The lack of responses seen in this trial also differed from the 21% response rate observed by the NCI Surgery Branch, using rIL-2 alone at an identical schedule and dose in 56 patients with renal cell carcinoma. Only minor differences in such recognized prognostic variables as performance status, tumor burden, and rIL-2 dose intensity were noted between this study and other trials reported by the NCI Surgery Branch and by the IL-2-LAK Working Group. Our analysis indicates that, because of the smaller number of patients in our trial, not enough subjects were included with the ideal characteristics to attain the 21% response rate seen in the NCI study. However, the precise nature of these characteristics remains unclear.

Original languageEnglish (US)
Pages (from-to)1202-1206
Number of pages5
JournalJournal of the National Cancer Institute
Volume82
Issue number14
StatePublished - Jul 18 1990

Fingerprint

Interleukin
Renal Cell Carcinoma
Surgery
Interleukin-2
Dose
Cells
National Cancer Institute (U.S.)
Cell
Cancer
Branch
Lymphokine-Activated Killer Cells
Toxicity
Tumors
Therapeutics
Schedule
Appointments and Schedules
Cycle
Renal cell carcinoma
Recombinant
Lymphokines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging

Cite this

Abrams, J. S., Rayner, A. A., Wiernik, P. H., Parkinson, D. R., Eisenberger, M., Aronson, F. R., ... Hawkins, M. J. (1990). High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma. Journal of the National Cancer Institute, 82(14), 1202-1206.

High-dose recombinant interleukin-2 alone : A regimen with limited activity in the treatment of advanced renal cell carcinoma. / Abrams, Jeffrey S.; Rayner, Anthony A.; Wiernik, Peter H.; Parkinson, David R.; Eisenberger, Mario; Aronson, Frederick R.; Gucalp, Rasim A.; Atkins, Michael B.; Hawkins, Michael J.

In: Journal of the National Cancer Institute, Vol. 82, No. 14, 18.07.1990, p. 1202-1206.

Research output: Contribution to journalArticle

Abrams, JS, Rayner, AA, Wiernik, PH, Parkinson, DR, Eisenberger, M, Aronson, FR, Gucalp, RA, Atkins, MB & Hawkins, MJ 1990, 'High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma', Journal of the National Cancer Institute, vol. 82, no. 14, pp. 1202-1206.
Abrams JS, Rayner AA, Wiernik PH, Parkinson DR, Eisenberger M, Aronson FR et al. High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma. Journal of the National Cancer Institute. 1990 Jul 18;82(14):1202-1206.
Abrams, Jeffrey S. ; Rayner, Anthony A. ; Wiernik, Peter H. ; Parkinson, David R. ; Eisenberger, Mario ; Aronson, Frederick R. ; Gucalp, Rasim A. ; Atkins, Michael B. ; Hawkins, Michael J. / High-dose recombinant interleukin-2 alone : A regimen with limited activity in the treatment of advanced renal cell carcinoma. In: Journal of the National Cancer Institute. 1990 ; Vol. 82, No. 14. pp. 1202-1206.
@article{ce3743e234674d2a851245f987d39c7a,
title = "High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma",
abstract = "Sixteen patients with metastatic renal cell carcinoma were treated with high-dose bolus recombinant interleukin-2 (rIL-2) alone at a dose and schedule identical to those that produced a 35{\%} response rate among 72 patients in a trial reported by the Surgery Branch, National Cancer Institute (NCI), Bethesda, Md, in which rIL-2 plus lymphokine-activated killer (LAK) cells was used for the treatment of renal cell carcinoma. Patients received two 5-day cycles of 100,000 Cetus U/kg (600,000 IU/kg) of rIL-2 infused intravenously over 15 minutes every 8 hours; each treatment cycle was separated by 1 week. No objective responses were seen. The toxicity of rIL-2 given alone at these high doses was similar to that noted with high-dose rIL-2-LAK cell therapy. The lack of responses seen in this trial also differed from the 21{\%} response rate observed by the NCI Surgery Branch, using rIL-2 alone at an identical schedule and dose in 56 patients with renal cell carcinoma. Only minor differences in such recognized prognostic variables as performance status, tumor burden, and rIL-2 dose intensity were noted between this study and other trials reported by the NCI Surgery Branch and by the IL-2-LAK Working Group. Our analysis indicates that, because of the smaller number of patients in our trial, not enough subjects were included with the ideal characteristics to attain the 21{\%} response rate seen in the NCI study. However, the precise nature of these characteristics remains unclear.",
author = "Abrams, {Jeffrey S.} and Rayner, {Anthony A.} and Wiernik, {Peter H.} and Parkinson, {David R.} and Mario Eisenberger and Aronson, {Frederick R.} and Gucalp, {Rasim A.} and Atkins, {Michael B.} and Hawkins, {Michael J.}",
year = "1990",
month = "7",
day = "18",
language = "English (US)",
volume = "82",
pages = "1202--1206",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "14",

}

TY - JOUR

T1 - High-dose recombinant interleukin-2 alone

T2 - A regimen with limited activity in the treatment of advanced renal cell carcinoma

AU - Abrams, Jeffrey S.

AU - Rayner, Anthony A.

AU - Wiernik, Peter H.

AU - Parkinson, David R.

AU - Eisenberger, Mario

AU - Aronson, Frederick R.

AU - Gucalp, Rasim A.

AU - Atkins, Michael B.

AU - Hawkins, Michael J.

PY - 1990/7/18

Y1 - 1990/7/18

N2 - Sixteen patients with metastatic renal cell carcinoma were treated with high-dose bolus recombinant interleukin-2 (rIL-2) alone at a dose and schedule identical to those that produced a 35% response rate among 72 patients in a trial reported by the Surgery Branch, National Cancer Institute (NCI), Bethesda, Md, in which rIL-2 plus lymphokine-activated killer (LAK) cells was used for the treatment of renal cell carcinoma. Patients received two 5-day cycles of 100,000 Cetus U/kg (600,000 IU/kg) of rIL-2 infused intravenously over 15 minutes every 8 hours; each treatment cycle was separated by 1 week. No objective responses were seen. The toxicity of rIL-2 given alone at these high doses was similar to that noted with high-dose rIL-2-LAK cell therapy. The lack of responses seen in this trial also differed from the 21% response rate observed by the NCI Surgery Branch, using rIL-2 alone at an identical schedule and dose in 56 patients with renal cell carcinoma. Only minor differences in such recognized prognostic variables as performance status, tumor burden, and rIL-2 dose intensity were noted between this study and other trials reported by the NCI Surgery Branch and by the IL-2-LAK Working Group. Our analysis indicates that, because of the smaller number of patients in our trial, not enough subjects were included with the ideal characteristics to attain the 21% response rate seen in the NCI study. However, the precise nature of these characteristics remains unclear.

AB - Sixteen patients with metastatic renal cell carcinoma were treated with high-dose bolus recombinant interleukin-2 (rIL-2) alone at a dose and schedule identical to those that produced a 35% response rate among 72 patients in a trial reported by the Surgery Branch, National Cancer Institute (NCI), Bethesda, Md, in which rIL-2 plus lymphokine-activated killer (LAK) cells was used for the treatment of renal cell carcinoma. Patients received two 5-day cycles of 100,000 Cetus U/kg (600,000 IU/kg) of rIL-2 infused intravenously over 15 minutes every 8 hours; each treatment cycle was separated by 1 week. No objective responses were seen. The toxicity of rIL-2 given alone at these high doses was similar to that noted with high-dose rIL-2-LAK cell therapy. The lack of responses seen in this trial also differed from the 21% response rate observed by the NCI Surgery Branch, using rIL-2 alone at an identical schedule and dose in 56 patients with renal cell carcinoma. Only minor differences in such recognized prognostic variables as performance status, tumor burden, and rIL-2 dose intensity were noted between this study and other trials reported by the NCI Surgery Branch and by the IL-2-LAK Working Group. Our analysis indicates that, because of the smaller number of patients in our trial, not enough subjects were included with the ideal characteristics to attain the 21% response rate seen in the NCI study. However, the precise nature of these characteristics remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0025345935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025345935&partnerID=8YFLogxK

M3 - Article

C2 - 2194036

AN - SCOPUS:0025345935

VL - 82

SP - 1202

EP - 1206

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 14

ER -